Long-term follow-up of angiod streaks

Publication
Article
Optometry Times JournalDecember digital edition 2020
Volume 12
Issue 12

Angioid streaks are due to Bruch membrane disintegration, not elastic deterioration

Nearly 2 and-half decades ago, we reported a case of angioid streaks which were determined to be secondary to iron deposition at the level of Bruch membrane. The underlying systemic condition responsible for this was AC hemoglobinopathy, a rare blood dyscrasia related to thallasemia and sickle-cell disease.1

In that publication, the clinical picture of angioid streaks was not that of the classical branching pattern, nor was the cause related to an elastic-tissue disorder, most prevalently pseudoxanthoma elasticum as classically described (think the PEPSI-trauma mnemonic: Pseudoxanthoma Elasticum, Paget’s disease of bone, Sickle cell anemia or other hemoglobinopathy [Thalassemias], Idiopathic).2-5 The patient was followed closely over many years during which the clinical picture evolved to the complication of choroidal neovascularization (CNV).

Following the case

Figure 1 is the presentation when the patient reported distorted vision and attended for an unscheduled visit. Visual acuity in the right eye was 20/80, and fluorescein angiography demonstrated occult CNV involving the macula (Figure 2). The patient was treated with photodynamic therapy, which was the standard for CNV due to age-related macular degeneration (AMD) at the time. On follow-up at 1 year, visual acuity stabilized at 20/80, and the right fundus is depicted in Figure 3. Eventually, the natural course of CNV evolved, and the right eye is shown in Figure 4.

The patient was monitored for changes in the fellow eye which did not show evidence of macular complications until 3 years later. The patient again reported disturbed vision involving the left eye (Figure 5). Visual acuity was 20/40. The prominent treatment for CNV at this point was intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents. The patient was treated at this point. At 1 year post-op, visual acuity was 20/40 (Figure 6). He maintained 20/40 visual acuity for the next 5 years at which time he was scheduled for cataract surgery (Figure 7).

This case illustrates the long-term follow-up of a patient who developed CNV secondary to an unusual presentation of angioid streaks. The mechanism for angioid streaks here is due to Bruch membrane becoming brittle, as opposed to elastic deterioration as is more common with other etiologies of angioid streaks.

The other point that can be gleaned from this case is the improvement of treatment for CNV. Photodynamic therapy was a revolution over laser treatment. The aim of this treatment was to maintain the baseline visual acuity. With the advent of anti-VEGF treatments, patient outcomes were improved to the point of improving visual acuity due to CNV. This has now become useful treatment methodologies for CNV due to a variety of etiologies.5

References

1. McBrayer GM, Semes L, Stephens GG. Angioid streaks and AC hemoglobinopathy--a newly discovered association. J Am Optom Assoc. 1993 Apr;64(4):250-3.

2. Agrawal R, Rosar AP, Lavric A. Multiple Choroidal Ruptures in a Patient With Angioid Streaks. JAMA Ophthalmol. 2017 Mar 9;135(3):e165466.

3. Johnson BW, Oshinskie L. Diagnosis and management of angioid streaks. J Am Optom Assoc. 1988;59(9):704-711.

4. Gurwood AS, Mastrangelo DL. Understanding angioid streaks. J Am Optom Assoc. 1997 May;68(5):309-24. Erratum in: J Am Optom Assoc 1997 Jul;68(7):406.

5. Chatziralli I, Saitakis G, Dimitriou E, Chatzirallis A, Stoungioti S, Theodossiadis G, Theodossiadis P. Angiod Streaks: A Comprehensive Review From Pathophysiology to Treatment. Retina. 2019 Jan;39(1):1-11.

Recent Videos
Dr. Mark Dunbar chats about his EyeCon 2024 presentation about diabetic eye care
Dr. Ferrucci summarizes his Vision Expo West presentations and shares clinical pearls for managing retinal cases.
Mohammad Rafieetary, OD, FAAO
Deborah Ferrington details a session on mitochondrial maintenance and retinal health in patients with AMD at ARVO 2024
Dr. John Sheppard discusses results from trials testing the efficacy of eye drops to treat dry eye disease
Danica Marrelli, OD, FAAO, AAO Dipl, co-chair of EnVision Summit chats about geographic atrophy and glaucoma panels
Steven Ferrucci, OD, FAAO - AAOpt
© 2024 MJH Life Sciences

All rights reserved.